Swiss Water Reports Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX : SWP) ('Swiss Water' or 'the Company'), a leading specialty coffee company and premium green coffee decaffeinator, is pleased to announce the following voting results of the Company's Annual General Meeting of Shareholders, which was held on Thursday, May 22, 2025.
Election of Directors
The Director nominees listed in the Management Information Circular for its Annual General Meeting of Shareholders were elected as Directors of Swiss Water. Voting results for individual Directors elected were as follows:
Votes For
Votes Against
Nominee
Number
Percentage
Number
Percentage
Frank A. Dennis
2,730,967
98.58%
39,302
1.42%
Roland W. Veit
2,440,525
88.10%
329,744
11.90%
Robert B. Johnston
2,432,875
87.82%
337,394
12.18%
Donald J. Tringali
2,723,317
98.31%
46,952
1.69%
Nancy L. McKenzie
2,728,667
98.50%
41,602
1.50%
Alan C. Wallace
2,732,467
98.64%
37,802
1.36%
Eric Yanagi
1,783,335
64.37%
986,934
35.63%
Appointment of Auditors
MNP LLP was appointed as auditors with 99.93% voting support.
About Swiss Water
Swiss Water Decaffeinated Coffee Inc. is a leading specialty coffee company and a premium green coffee decaffeinator that employs the proprietary Swiss Water® Process to decaffeinate green coffee without the use of chemical solvents such as methylene chloride. It also owns Seaforth Supply Chain Solutions Inc., a green coffee handling and storage business. Both businesses are located in Delta, British Columbia, Canada.
Additional Information
A more detailed discussion of Swiss Water Decaffeinated Coffee Inc.'s recent financial results is provided in the Company's Management Discussion and Analysis filed on SEDAR+ www.sedarplus.ca and Company's website https://investor.swisswater.com/financial-information/.
For more information, please contact:
Iain Carswell, Chief Financial OfficerSwiss Water Decaffeinated Coffee Inc.Phone: 604-420-4050Email: investor-relations@swisswater.comWebsite: investor.swisswater.com
Forward-Looking Statements:
Certain statements in this press release may constitute 'forward-looking' statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements may include such words as 'may', 'will', 'expect', 'believe', 'plan' and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance, as well as management's current estimates, but which are based on numerous assumptions and may prove to be incorrect. These statements are neither promises nor guarantees but involve known and unknown risks and uncertainties, including, but not limited to, risks related to processing volumes and sales growth, operating results, the supply of utilities, the supply of coffee, general industry conditions, commodity price risks, technology, competition, foreign exchange rates, construction timing, costs and financing of capital projects, a potential impact of the COVID-19 pandemic, and general economic conditions. The forward-looking statements and financial outlook information contained herein are made as of the date of this press release and are expressly qualified in their entirety by this cautionary statement. Except to the extent required by applicable securities law, Swiss Water undertakes no obligation to publicly update or revise any such statements to reflect any change in management's expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those described herein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Ecorobotix Unveils Lettuce Thinning Algorithm, Delivering Precision and Labor Savings for Lettuce Growers
PASCO, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Ecorobotix, an AI company specializing in precision agriculture, announces the launch of its new Lettuce Thinning algorithm, expanding the capabilities of its ARA Ultra High Precision (UHP) Sprayer to offer one of the most advanced automated thinning solutions on the market. This new functionality is now available to ARA users via a software license—enabling precise, plant-by-plant thinning without the need for additional equipment or hand labor. 'This is a major milestone for our customers in the lettuce industry,' said Katerina Lee Regional Crop Care Manager at Ecorobotix. 'We've combined the power of AI with the reliability of ARA's ultra-high precision spraying platform to eliminate one of the most time-consuming and labor-intensive tasks in the field—thinning.' Key Advantages of the Lettuce Thinning Algorithm: Replaces Manual Labor: Growers can eliminate thinning crews and reduce labor costs. The ARA system performs thinning autonomously with just one operator. Superior Uniformity: ARA uses mathematical precision to define plant spacing, ensuring consistent stands and removing human variability. Faster Field Coverage: ARA outpaces manual crews, covering fields quickly while maintaining accuracy. Easy Integration: Existing ARA owners can activate lettuce thinning through a simple license subscription. Multi-Purpose Platform: The same ARA sprayer can be used for weeding and other crop protection tasks, allowing year-round value from one machine. True Plant Selection: ARA distinguishes between crops and weeds on the planting line, preserving the right plant every time. Simple Operation: With an intuitive interface and minimal setup required, the ARA sprayer is easy for any operator to use. This innovation is part of Ecorobotix's broader mission to help growers reduce labor, increase yield potential, and improve operational efficiency through cutting-edge Plant-by-Plant AI technology. Lettuce producers interested in the Lettuce Thinning algorithm or scheduling a live demo can sign up HERE. About EcorobotixEcorobotix is an AI company that specializes in precision agriculture. Its flagship product, the ARA Ultra High Precision Sprayer delivers treatments only where needed, using advanced computer vision and AI. Designed to reduce chemical usage and manual labor while improving crop performance, Ecorobotix technologies are redefining how growers treat every plant in the field. A photo accompanying this announcement is available at CONTACT: Media Contact: Chrissy Wozniak U.S. Marketing & Communications Manager Ecorobotix 239-841-9347 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Cannabis Research Reveals Optimal Water Activity Levels for Enhanced Pre-Roll Quality and Profitability
First-Of-Its-Kind, Peer-Reviewed Study Combines Laboratory Analysis With Consumer Testing To Optimize Cannabis Smoking Experience RENTON, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Custom Cones USA, in partnership with DaySavers, the Cannabis Research Coalition, and The Network of Applied Pharmacognosy (NAP), shares key findings from Phase I Science of Smokability study, a multi-year research project that is transforming understanding of cannabis cultivation, processing, and consumption. The revolutionary study, led by Dr. Allison Justice, Dr. Miyabe Shields, Dr. Riley Kirk, and Dr. Markus Roggen, represents the first peer-reviewed scientific assessment to examine how various cultivation and production techniques affect cannabis products from the consumer perspective, combining laboratory smoking machine analysis with comprehensive consumer surveys. Key Findings Reveal 0.65 aW as Optimal Water Activity Level Phase I research focused on water activity and moisture content effects on cannabis pre-rolls, with results demonstrating that products maintained at 0.65 aW (water activity) consistently delivered superior performance across multiple metrics: Cannabinoid Delivery: Pre-rolls at 0.65 aW produced the highest cannabinoid concentration in smoke, with 0.85 aW samples delivering only 30% of the cannabinoid content compared to optimal levels Terpene Content: The 0.65 aW samples yielded the highest terpene content, delivering more pronounced flavor profiles Consumer Experience: Survey participants reported that 0.65 aW pre-rolls provided a less irritating smoking experience, while 0.45 aW samples produced harsher, more irritating experiences Significant Financial Implications for Cannabis Producers The study reveals substantial economic benefits for producers maintaining proper water activity levels. The research indicates that the difference between 0.45 aW and 0.65 aW water activity levels corresponds to approximately 18.14 grams per pound of flower—representing potential revenue gains of $27.20 per pound at an assumed market price of $1.50 per gram. "This represents about 4% of revenue per pound of flower," explained Harrison Bard, CEO of Custom Cones USA. "For cannabis producers, optimizing water activity levels can simultaneously improve product quality while enhancing profitability." Innovative Research Methodology Sets New Industry Standard Unlike previous cannabis studies, the Science of Smokability employs a unique dual-methodology approach: Laboratory Analysis: Utilizing sophisticated smoking machines and Combustion Smoke Analyzer SCS technology to measure precise cannabinoid and terpene concentrations in smoke Consumer Testing: Comprehensive surveys from paid participants who received pre-rolls in specialized airtight containers to maintain specific water activity levels The study examined high-quality hemp pre-rolls from The Hemp Mine's "FunDip" strain, stabilized at three different water activity levels using digital hygrometers, 0.45 aW, 0.65 aW, and 0.85 aW. Pre-rolls were manufactured on professional pre-roll machines to ensure consistency. 'The Cambustion machine allowed us to test the composition of the smoke instead of the raw material (flower),' said Dr. Shields. 'Every time we light up, there's a chemical reaction, and the smoking machine allows us to look at what molecules are reaching our lungs after they've been smoked.' When combined with consumer feedback, the results provide a comprehensive view of how different production and cultivation variables impact the final consumer version of products. Industry Impact and Implications The research underscores the critical importance of proper curing and moisture management in cannabis production. As the study authors note: "By optimizing water activity levels, it may be possible to enhance the delivery of desirable compounds, such as cannabinoids and terpenes while minimizing the presence of potentially harmful elements." The findings have immediate practical applications for cannabis producers using automated pre-roll filling machines, which typically benefit from lower moisture content around 9%, corresponding to approximately 0.65 aW. 'Our results emphasize that staying as close as possible to the 0.65 threshold allows a higher quality smoking experience,' said Dr. Kirk. About the Science of Smokability Study The Science of Smokability is a multi-year research initiative spearheaded by Custom Cones USA and DaySavers, in partnership with leading cannabis research organizations, the Cannabis Research Coalition and The Network of Applied Pharmacognosy (NAP). The study aims to provide evidence-based insights into cannabis cultivation, processing, and consumption through rigorous scientific methodology. Phase I of the Science of Smokability focused on the effects of water activity and moisture content on the smoking process. Phase II will look at the impact of nutrients on the smokeability and chemistry of smoking. About Custom Cones USA Founded in 2017 by Harrison Bard and Fredrik Rading, Custom Cones USA is a leading pre-roll resource in the cannabis industry. The team has a wealth of knowledge about all aspects of pre-roll manufacturing and the entire pre-roll sector of the cannabis space. From custom-branded pre-rolled cones and wholesale bulk cones, to completely customized pre-roll packaging projects and pre-roll machines, they offer expertise and solutions to companies big and small in all sectors of the pre-roll space. Custom Cones USA wants to help their customers operate with relative ease and ensure both the companies and their customers to have the highest quality smoking experience. Media Contact: Clarissa Colondo customcones@ Editor's Note: Content, brand logos, and additional data visualizations are available for media or brand use with attribution. Interview opportunities with Custom Cones USA analysts are available upon in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029
'Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research's global market analysis of nanotechnology in oncology.' Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques, companies such as AstraZeneca, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb are developing next-generation solutions to enhance therapeutic effectiveness while minimizing harm to healthy cells. According to the report, growing cancer prevalence, rising government funding, and increased pharmaceutical R&D spending are reshaping innovation strategies across the oncology landscape. The global market is projected to grow at a CAGR of 17.4% from 2024 to 2029. As North America continues to lead market expansion and new nanomedicine applications evolve globally, stakeholders must navigate regulatory complexity, manufacturing scalability, and long-term safety considerations to harness the full potential of this technology. Market Overview: Key Insights and Forecast BCC Research's latest report, Nanotechnology in Cancer Treatment: Technologies and Global Markets, delivers a detailed evaluation of the evolving oncology landscape through the lens of nanomedicine. It explores how advances in nanostructured materials, targeted delivery systems, and diagnostic innovations are shaping the future of cancer treatment across major regions. The global market was valued at $102.4 billion in 2023 and is projected to reach $265.4 billion by the end of 2029. The report delivers forward-looking insights based on current market trends and expected developments over the forecast period. It provides a strategic analysis of major segments by product type and cancer type, along with comprehensive coverage of revenue trends, regulatory frameworks, ESG priorities, technological advancements, and regional market shifts. Market Leadership in Transition The cancer nanomedicine space is evolving rapidly, with companies investing in product differentiation and late-stage R&D. Liposomes remain the most commercially established carriers, while polymeric nanoparticles and dendrimers are seeing increased use due to their payload capacity and tumor selectivity (Chapter 6: Market Segment Analysis). Leading companies such as Pfizer, Novartis AG, and Jazz Pharmaceuticals are developing tailored nanocarrier systems for specific cancer indications, with a focus on breast and lung cancers. These therapies are being designed for better tumor penetration, reduced off-target toxicity and improved treatment outcomes (Chapter 7: Competitive Intelligence). Emerging Technologies and Investment Trends Innovation in nanomedicine is being fueled by multifunctional systems that integrate diagnosis, therapy, and monitoring. Technologies including quantum dots, cancer stem cell-targeting particles, and nanorobotics are moving closer to clinical translation, offering new capabilities in image-guided therapy and adaptive dosing. Strong capital inflow and increased partnerships between biotech firms and research institutions are accelerating development across early and mid-stage pipelines. These trends are unlocking commercialization potential, especially in minimally invasive therapies and immuno-nanomedicine (Chapter 5: Emerging Technologies and New Developments). Pipeline Assessment and Applications The oncology pipeline is steadily embracing nanotechnology as a cornerstone for targeted treatment development. Companies are advancing nanoparticle-based drug carriers with enhanced tumor penetration, improved bioavailability and reduced toxicity. These innovations are driving late-stage R&D across different types of cancers, such as breast and lung cancers, leukemia and melanoma. In parallel, there is growing interest in integrating diagnostic and therapeutic functions into single nanosystems. Platforms capable of simultaneous drug delivery and real-time tumor tracking are gaining momentum, offering the potential for adaptive dosing and early relapse detection (Chapter 6: Market Segment Analysis). Regulatory and Access Challenges Regulatory agencies, such as the U.S. FDA, European Medicines Agency (EMA), and other international bodies, are actively evolving frameworks to support the safe and effective approval of nanoscale cancer therapies. As manufacturers scale production, they must comply with stringent requirements related to materials handling, product traceability and lifecycle oversight (Chapter 4: Regulatory Landscape). Challenges such as development costs, access limitations in low-income regions, and a shortage of oncology specialists trained in nanomedicine are slowing down broader adoption. Addressing these issues is essential to achieving long-term growth and equitable global impact (Chapter 3: Market Dynamics). Strategic Outlook: The Road Ahead With nanotechnology's role in oncology continuing to expand, companies are aligning R&D with long-term goals around innovation, clinical efficacy, and accessibility. Key companies are developing platforms that support patient-centered care, data-driven treatment personalization, and integration across diagnostic and therapeutic pathways (Chapter 2: Market Overview). As infrastructure improves and global interest in targeted therapies grows, nanomedicine is expected to become a cornerstone of modern cancer care. Firms prioritizing early diagnosis, adaptive delivery and long-term monitoring will be best positioned to lead the market forward (Chapter 7: Competitive Intelligence). Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $102.4 billion Market size forecast $265.4 billion Growth rate CAGR of 17.4% for the forecast period of 2024-2029 Segments covered Product type and cancer type Regions covered North America, Europe, Asia-Pacific, South America, Rest of the World Countries covered The U.S., Canada, Mexico, Germany, France, Italy, Spain, the U.K., Austria, Sweden, Denmark, Poland, Turkey, Switzerland, the Netherlands, China, Japan, India, South Korea, Australia, Thailand, Singapore, Malaysia, New Zealand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru, Middle East and Africa Market drivers Increasing prevalence of cancer cases globally. Rise in government funding and pharmaceutical R&D spending. Nanoparticles in cancer treatment: Advantages. Precision targeting of cancer cells with nanomaterials. Additional Insights: Ultra-small and highly efficient: Nanoparticles are often smaller than a single cell; thus, it is easier for them to penetrate tumors and deliver drugs directly to cancer cells. Stealth functionality: These particles can be engineered to "cloak" themselves from the immune system, allowing them to circulate longer within the bloodstream. Multifunctional carriers: Nanoparticles can transport multiple drugs simultaneously, enabling combination therapies in a single delivery. Energy-interactive: They can absorb energy from external sources, supporting their role in advanced imaging or therapeutic enhancement. Next-level diagnostics: Nanoparticles can serve as highly sensitive imaging agents, enhancing early diagnosis and treatment precision. Leading companies include: AstraZeneca Baxter Boston Scientific Corp. Bristol-Myers Squibb Co. F. Hoffmann-La Roche Ltd. Jazz Pharmaceuticals Inc. Les Laboratoires Servier Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301
